Cardiac ischemia causes the interruption of coronary blood flow and decline of myocardial contraction ability.
During acute myocardial ischemia, the ability of binding ions such as copper, zinc, and cobalt is decreased; therefore a form of albumin is produced, which is described as ischemia modified albumin (IMA).
Since delays in and interruptions of CPR degenerate VF into a finer and lower amplitude signal while repeated futile shocks increase the severity of myocardial damage, the ability to gain information concerning the state of the myocardium and to optimize the timing of defibrillation would allow therapy to be tailored to an individual heart [ 7– 11].
Myocardial tissue lacks the ability to significantly regenerate itself following a myocardial infarction, thus tissue engineering strategies are required for repair.
The positive effect of ivabradine on angina pectoris symptoms and myocardial ischaemia, and its ability to reduce myocardial ischemia, make it an important agent in the management of patients with stable CAD.
The findings also inform new hypothesis for the role of HNE in myocardial abnormalities through its ability to inhibit mNADP-ICDH activity and to induce CTGF and Col I expression in isolated cardiomyocytes.
Our previous studies also revealed that Cav-3 KO mice, which decrease the number of myocardial caveolae, lose the ability to undergo cardioprotection from ischemia/reperfusion injury both in vitro and in vivo models [ 14– 17].
Considering that the VO2 max is determined by cardiac (cardiac output) and peripheral (arterio-venous oxygen difference) factors, this response can be a result of reduced ability of myocardial contraction and failed relaxation of heart fibers.
Transplantation of hMSCs ameliorate heart function, but proliferative ability and myocardial protection decrease significantly in MSCs obtained from patients with CAD+DM compared with cultures from patients with CAD alone, possibly as a result of differences in Bcl-2 protein expression and reduced anti-apoptosis.
Furthermore, the use of cardiac 82Rb PET/CT has been promoted by its ability to quantify myocardial blood flow (MBF) and myocardial flow reserve (MFR) noninvasively and routinely [9, 10].
